Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYTROTCMKTS:ENZNNASDAQ:GNMXNASDAQ:LIFENASDAQ:TROV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsENZNEnzon Pharmaceuticals$0.07$0.08$0.06▼$0.23N/A0.3312,737 shsN/AGNMXAevi Genomic Medicine$0.17$0.17$0.11▼$0.35$12.89M1.133.16 million shs2.95 million shsLIFEaTyr Pharma$1.60-1.2%$1.85$1.08▼$2.70$108.71M1.25514,669 shs158,056 shsTROVCardiff Oncology$4.37-2.9%$16.75$0.70▼$3.46$48.12M1.04648,892 shs832,218 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTRLadRx0.00%0.00%0.00%0.00%0.00%ENZNEnzon Pharmaceuticals-0.06%-23.67%+20.60%-17.30%-64.70%GNMXAevi Genomic Medicine0.00%0.00%0.00%0.00%0.00%LIFEaTyr Pharma+1.89%-7.95%-19.00%+8.00%-13.37%TROVCardiff Oncology-4.79%-25.81%-15.47%+199.32%+191.33%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGNMXAevi Genomic MedicineN/AN/AN/AN/AN/AN/AN/AN/ALIFEaTyr Pharma1.9642 of 5 stars3.43.00.00.03.21.70.0TROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTRLadRxN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AGNMXAevi Genomic MedicineN/AN/AN/AN/ALIFEaTyr Pharma2.75Moderate Buy$23.671,379.17% UpsideTROVCardiff OncologyN/AN/AN/AN/ACurrent Analyst RatingsLatest TROV, LIFE, GNMX, CYTR, and ENZN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTRLadRxN/AN/AN/AN/AN/AN/AENZNEnzon Pharmaceuticals$30KN/AN/AN/AN/AN/AGNMXAevi Genomic MedicineN/AN/AN/AN/A$0.12 per shareN/ALIFEaTyr Pharma$353K307.95N/AN/A$1.54 per share1.04TROVCardiff Oncology$250K192.47N/AN/A$0.94 per share4.65Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/AENZNEnzon Pharmaceuticals$1.37M$0.017.24∞N/AN/A46.47%2.92%N/AGNMXAevi Genomic Medicine-$30.77M-$0.50N/A∞N/AN/A-898.31%-286.73%N/ALIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)TROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ALatest TROV, LIFE, GNMX, CYTR, and ENZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023ENZNEnzon PharmaceuticalsN/A$0.01+$0.01$0.01N/AN/A3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTRLadRxN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AGNMXAevi Genomic MedicineN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTRLadRxN/AN/AN/AENZNEnzon PharmaceuticalsN/A27.6227.62GNMXAevi Genomic MedicineN/A0.650.65LIFEaTyr Pharma0.026.276.27TROVCardiff Oncology0.122.372.37OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTRLadRxN/AENZNEnzon PharmaceuticalsN/AGNMXAevi Genomic Medicine7.03%LIFEaTyr Pharma61.72%TROVCardiff Oncology9.99%Insider OwnershipCompanyInsider OwnershipCYTRLadRxN/AENZNEnzon Pharmaceuticals0.27%GNMXAevi Genomic Medicine43.80%LIFEaTyr Pharma3.70%TROVCardiff Oncology0.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableENZNEnzon PharmaceuticalsN/AN/AN/ANot OptionableGNMXAevi Genomic Medicine1477.71 millionN/AOptionableLIFEaTyr Pharma5667.94 million65.43 millionOptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTROV, LIFE, GNMX, CYTR, and ENZN HeadlinesSourceHeadlineCardiff Oncology shares surge as first-line colorectal cancer study beginsbioworld.com - March 2 at 9:54 AMCardiff Oncology Stock (NASDAQ:CRDF) Dividends: History, Yield and Datesbenzinga.com - February 23 at 8:35 AMCardiff Oncology’s Onvansertib Shows Promise: An Analysis of the Buy Rating Recommendationmarkets.businessinsider.com - September 29 at 7:51 AMStocks to Watch: MillerKnoll, Cardiff Oncology, Morphic Holdingsmarketwatch.com - September 26 at 8:02 PMCardiff Oncology Shares Up 26% After Potential Cancer Treatment Advancesmarketwatch.com - August 8 at 1:26 PMH.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)markets.businessinsider.com - August 8 at 8:26 AMCardiff Oncology (NASDAQ: CRDF)fool.com - May 27 at 10:27 PMCheap Flights from Cardiff to Bordeauxskyscanner.net - May 15 at 10:11 AMCheap Flights from Cardiff to Corkskyscanner.net - May 2 at 5:42 PMCardiff City FCwalesonline.co.uk - April 29 at 12:09 AMBenetton 27-23 Cardiff: Welsh side's Challenge Cup over after tight affair in Italywalesonline.co.uk - April 25 at 1:30 PMCardiff Oncologyforbes.com - January 13 at 4:28 PMCardiff hostel plagued by drug users and anti-social behaviour goes up for salewalesonline.co.uk - January 11 at 3:27 PMChristmas tree collection dates in Cardiffwalesonline.co.uk - January 11 at 3:27 PMAs Onvansertib fumarate moves closer to clinical approval, what is the likelihood that the drug will be approved?pharmaceutical-technology.com - January 4 at 6:32 AMCardiff Oncology: Staying The Courseseekingalpha.com - December 14 at 9:58 AMCardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updatesfbherald.com - November 4 at 5:22 AMClear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buyingmarkets.businessinsider.com - October 16 at 3:13 PMCardiff Oncology, Inc. (CRDF)finance.yahoo.com - September 29 at 6:59 PMCRDF Cardiff Oncology, Inc.seekingalpha.com - September 24 at 9:47 AMCardiff drops its lead prostate cancer program, sending shares into a tailspinendpts.com - September 15 at 6:24 PMLooking Into Cardiff Oncology's Return On Capital Employedmsn.com - August 25 at 1:45 AMCardiff Oncology: Down But Not Outseekingalpha.com - August 22 at 7:24 PMCardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?finance.yahoo.com - July 28 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Cheap Dividend Stocks: Which to Buy NowApril 1, 2024 9:55 AMView 5 Cheap Dividend Stocks: Which to Buy NowBlackstone’s $10 Billion Bet on Property Prices Going UpApril 11, 2024 7:30 AMView Blackstone’s $10 Billion Bet on Property Prices Going UpAll Headlines Company DescriptionsLadRxNASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Enzon PharmaceuticalsOTCMKTS:ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.Aevi Genomic MedicineNASDAQ:GNMXAevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Cardiff OncologyNASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.